Morgan Stanley Maintains Equal-Weight on Sage Therapeutics, Raises Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Vikram Purohit has maintained an Equal-Weight rating on Sage Therapeutics (NASDAQ:SAGE) and raised the price target from $20 to $22.

February 28, 2024 | 6:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Sage Therapeutics and increased the price target from $20 to $22.
The increase in price target by a reputable analyst like Vikram Purohit from Morgan Stanley suggests a positive outlook on the stock, potentially leading to short-term price appreciation. The Equal-Weight rating indicates that the stock is expected to perform in line with the market or sector, but the raised target price signals confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100